ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients

NCT04588311 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

2500

Enrollment

OTHER

Sponsor class

Conditions

Trauma
Traumatic Injury
Traumatic Brain Injury
Wounds and Injuries
Penetrating Injury
Blunt Injury
Major Trauma
Multiple Trauma

Interventions

DRUG: Epoetin Alfa 40000 UNT/ML
DRUG: Sodium Chloride 0.9%

Sponsor

Australian and New Zealand Intensive Care Research Centre

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]